MX2022011089A - Peptidos como agonistas selectivos del receptor de gip. - Google Patents

Peptidos como agonistas selectivos del receptor de gip.

Info

Publication number
MX2022011089A
MX2022011089A MX2022011089A MX2022011089A MX2022011089A MX 2022011089 A MX2022011089 A MX 2022011089A MX 2022011089 A MX2022011089 A MX 2022011089A MX 2022011089 A MX2022011089 A MX 2022011089A MX 2022011089 A MX2022011089 A MX 2022011089A
Authority
MX
Mexico
Prior art keywords
selective
receptor agonists
gip receptor
peptides
treatment
Prior art date
Application number
MX2022011089A
Other languages
English (en)
Inventor
Katrin Lorenz
Andreas Evers
Michael Wagner
Dirk Gretzke
Stefania Pfeiffer-Marek
Thomas Boehme
Tim Kloeckener
Anish Konkar
Ziyu Li
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2022011089A publication Critical patent/MX2022011089A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a péptidos que son agonistas selectivos del receptor de GIP y su uso médico, por ejemplo, en el tratamiento de trastornos del síndrome metabólico, incluyendo diabetes y obesidad, hiperglucemia, así como el tratamiento de trastornos asociados con náuseas y vómitos.
MX2022011089A 2020-03-06 2021-03-04 Peptidos como agonistas selectivos del receptor de gip. MX2022011089A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305238 2020-03-06
PCT/EP2021/055430 WO2021175974A1 (en) 2020-03-06 2021-03-04 Peptides as selective gip receptor agonists

Publications (1)

Publication Number Publication Date
MX2022011089A true MX2022011089A (es) 2022-10-03

Family

ID=69960584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011089A MX2022011089A (es) 2020-03-06 2021-03-04 Peptidos como agonistas selectivos del receptor de gip.

Country Status (9)

Country Link
US (1) US20230103631A1 (es)
EP (1) EP4110800A1 (es)
JP (1) JP2023519516A (es)
KR (1) KR20220145888A (es)
CN (1) CN115884982A (es)
AU (1) AU2021229621B2 (es)
CA (1) CA3174635A1 (es)
MX (1) MX2022011089A (es)
WO (1) WO2021175974A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2023031455A1 (en) * 2021-09-06 2023-03-09 Sanofi Sa New peptides as potent and selective gip receptor agonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003268621B2 (en) 2002-10-02 2009-01-15 Zealand Pharma A/S Stabilized exendin-4 compounds
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104902919B (zh) 2012-12-21 2018-11-20 赛诺菲 Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
JP6898231B6 (ja) 2014-10-29 2021-07-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐアゴニスト化合物及び方法
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
WO2019211451A1 (en) 2018-05-04 2019-11-07 Novo Nordisk A/S Gip derivatives and uses thereof
WO2020023386A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Gip/glp1 co-agonist compounds

Also Published As

Publication number Publication date
US20230103631A1 (en) 2023-04-06
JP2023519516A (ja) 2023-05-11
AU2021229621B2 (en) 2023-08-31
WO2021175974A1 (en) 2021-09-10
EP4110800A1 (en) 2023-01-04
CN115884982A (zh) 2023-03-31
KR20220145888A (ko) 2022-10-31
CA3174635A1 (en) 2021-09-10
AU2021229621A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
CR20230330A (es) Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
MX2022011089A (es) Peptidos como agonistas selectivos del receptor de gip.
MX2019007584A (es) Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada.
MX2019010907A (es) Agonistas del receptor x farnesoide, y usos de los mismos.
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
MX362190B (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
GT201500049A (es) Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico
NZ732000A (en) Gip and glp-1 co-agonist compounds
WO2018157171A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
HK1136943A1 (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2006121860A3 (en) Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2011006315A (es) Analogos de glucagon.
MX2015014408A (es) Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
MX2022011277A (es) Proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1 para usarse en transtornos metabolicos.
BR112019011144A2 (pt) compostos como agonistas peptídicos de receptor de glp1/glucagon/gip
WO2010054326A3 (en) C-terminal fragments of glucagon-like peptide-1 (glp-1)
MX362527B (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
MX2023000303A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
BR112022007721A2 (pt) Método para o tratamento da demência
MX366685B (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.